Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Cancer Cell. 2009 Mar 3;15(3):232–239. doi: 10.1016/j.ccr.2009.01.021

Figure 1. Accelerated Experimental Metastasis and Decreased Survival after Short-Term Sunitinib Treatment before and after Intravenous Tumor Inoculation.

Figure 1

(A) 231/LM2-4LUC+ cells were injected into the tail vein of SCID mice that received vehicle (group A) or short-term sunitinib treatment daily for 7 days either before (group B) or after tumor inoculation (group C). Quantification of bioluminescence showed accelerated tumor growth in groups B and C compared with controls. A representative experiment is shown. Group A, n = 10; group B, n = 5; group C, n = 10. Data are presented as mean ± SD.

(B) Kaplan-Meier survival curve shows significantly decreased median survival of mice in group B (log-rank test, p = 0.0055) and group C (log-rank test, p < 0.0001) compared with group A. Data represent a summary of multiple experiments. Group A, n = 31; group B, n = 11; group C, n = 19. 0.001 < **p < 0.01; ***p < 0.001.

(C) Representative images for each group taken 1, 7, and 27 days following tumor implantation, with increased metastasis visible in sunitinib-treated mice. Sunitinib dose and treatment schedule were performed as illustrated in (A).